Advancing Alopecia Areata Classification and Care

Alopecia areata (AA) is an autoimmune condition in which patients experience varying degrees of hair loss.¹ Therefore, estimating severity is crucial for proper diagnosis. Determining the extent of hair loss is essential for making treatment decisions, monitoring patient improvement, and predicting long-term outcomes,¹ which underscores the need for standardized instruments in clinical practice and research. 
Several assessment tools are currently in use to quantify AA severity.¹ The Severity of Alopecia Tool (SALT) is a commonly used objective method for determining scalp hair loss.²

Alopecia areata (AA) is a common autoimmune disease that causes nonscarring hair loss; it often presents as one or more bald patches on the scalp, but in severe cases, it can lead to complete scalp hair loss (alopecia totalis) or body hair loss (alopecia universalis).¹ Affecting 2% of the global population, AA poses unique diagnostic and classification challenges due to its diverse presentations and significant psychosocial impacts.¹ Despite the different methods available for classifying severity, there remains a need to evaluate and refine these classifications.¹

Reliable Classification Remains an Unmet Need
Diagnostic criteria for alopecia areata (AA) aim to identify the condition across its various forms, while classification criteria focus on grouping patients based on specific characteristics to guide treatment. The main classification method currently used is the Severity of Alopecia Tool (SALT), which assesses scalp hair loss in defined areas.² The SALT score ranges from 0% (no hair loss) to 100% (complete baldness) and provides a standardized way to measure the extent of hair loss. The scalp is divided into four regions: the vertex (40%), right profile (18%), left profile (18%), and posterior or nape area (24%).² 

While the SALT scoring system is effective for determining AA severity, physicians and researchers must understand its limitations to ensure comprehensive patient care.2 For example, terms such as "severe" and "extreme" are not consistently defined, which can complicate discussions between patients and providers regarding disease severity and progression.^2,3

An in-depth AA classification system would address these limitations, helping to standardize how severity is assessed across cases.¹ Factors beyond scalp hair loss—such as eyebrow and eyelash involvement, nail and body hair loss, and psychosocial impacts—are crucial for accurate severity categorization.¹ Recognizing this, U.S. researchers have developed an updated framework that begins with the degree of scalp hair loss and includes non-scalp hair features, treatment response, and prognosis markers (eg, positive hair pull test).¹ This multidimensional approach provides a more inclusive view of disease complexity and patient impact.¹

Incorporating Quality of Life Assessment
The emotional toll of AA is prominent, impacting patient quality of life (QoL) as much as physical symptoms do.¹ The Skindex-AA and the Hospital Anxiety and Depression Scale (HADS) are valuable tools for capturing the AA-specific effects on emotional well-being.¹ In practice, these tools provide insight into patient challenges—ranging from self-esteem to daily functioning—and underscore the importance of integrating psychosocial factors into severity assessments.¹ Such patient-reported outcomes often correlate more strongly with quality of life than do traditional measures such as SALT, suggesting that effective AA care requires understanding both visible symptoms and patient experiences.¹

The Skindex-16 survey focuses on the most impactful aspects of skin conditions and includes additional questions not included in the original Skindex-29 that address issues such as the persistence or recurrence of symptoms.⁴ Measuring the extent the patient is “bothered” by each symptom rather than symptom frequency provides a more direct assessment of how skin conditions affect quality of life.⁴ Skindex 16’s single-page design reduces respondent burden.⁴ For conditions such as alopecia areata, its emphasis on emotional and social "bother" affords a deeper understanding of impacts on self-image, social interactions, and emotional well-being.⁴

The Hospital Anxiety and Depression Scale (HADS) is frequently used to evaluate psychological symptoms in various medical conditions, including AA.¹ It consists of 2 subscales—Anxiety and Depression—with 7 questions each, scored from 0 to 21.1 Scores of 8 or above indicate notable anxiety or depression, and scores of 11 or higher signify clinically significant cases.¹ While HADS is valuable for assessing the psychological impact of AA, its scores have not been incorporated as criteria within any official AA classification system.¹

Moving in the Right Direction
A consensus-based AA severity framework offers a reliable foundation for consistent assessments in both clinical and research settings.¹ Dermatologists and researchers agree that a structured classification system will improve AA care by tailoring treatments to each patient's needs.¹ As new treatments emerge, this framework will allow for better treatment matching, improving outcomes across all severity levels.¹ 

Additionally, a shared classification language can help patients better understand their AA severity and treatment options.¹ This new multidimensional framework is a significant step forward in classifying AA. Taking into consideration factors beyond scalp hair loss gives dermatologists a well-rounded way to assess AA’s impact on physical, emotional, and social health. In both clinical practice and research, this framework provides a consistent way to measure AA severity, supporting more personalized care and better long-term outcomes.

References:

1. King BA, Senna MM, Ohyama M, et al. Defining severity in alopecia areata: current perspectives and a multidimensional framework. Dermatol Ther (Heidelb). 2022;12(4):825-834. doi:10.1007/s13555-022-00711-3
2. Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines—part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440-447. doi:10.1016/j.jaad.2003.09.032.
3. Olsen EA, Canfield D. SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. J Am Acad Dermatol. 2016;75(6):1268-1270. doi:10.1016/j.jaad.2016.08.042
4. Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30(2):231-xiii. doi:10.1016/j.det.2011.11.003